Moreover, low IGF‐1 action is relevant to humans because of its link to less cancer risk (Renehan et al., 2004), an observation that spurred the development of IGF‐1R antagonists as a clinical cancer treatment (Pollak, 2012). The gene discussed is IGF1R; the disease is cancer.